SCHEDULE: Vanguard Group Reports Zero Anika Therapeutics Stake

The Vanguard Group has reported 0% beneficial ownership of Anika Therapeutics Inc. common stock following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 8 to Schedule 13G for Anika Therapeutics Inc. common stock.
• The filing indicates The Vanguard Group now beneficially owns 0 shares, representing 0% of the class.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions will now report their beneficial ownership separately (on a disaggregated basis) in accordance with SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities held by these subsidiaries.
• The subsidiaries and business divisions continue to pursue the same investment strategies as previously.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update from The Vanguard Group regarding its internal reporting structure, with no direct impact on Anika Therapeutics Inc.'s fundamentals or investment prospects.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that this filing reflects a common practice among large institutional investors like The Vanguard Group to periodically adjust their internal reporting structures for beneficial ownership, often in response to regulatory guidance or internal operational efficiencies. The disaggregated reporting, as permitted by SEC Release No. 34-39538, allows for clearer delineation of ownership by specific entities within a larger group, without necessarily indicating a change in overall investment strategy or a divestment from the underlying company by the broader Vanguard ecosystem.

Stakeholder Impact

• Shareholders of Anika Therapeutics Inc. should note that while The Vanguard Group, Inc. itself now reports 0% beneficial ownership, the underlying investment positions may still be held by its subsidiaries, which will report separately. This is a change in reporting structure, not necessarily a full divestment by the broader Vanguard organization.

Key Dates

Keywords

Vanguard Group, Anika Therapeutics, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Ownership Change, Investment Management, Common Stock